MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Diagnosis & Differentiation

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Lung Cancer 2018 November [Link] Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Sato A, Tsujimura T, Ueda H, Makihata S, Kato F, Iwasaki A, Nabeshima K Abstract OBJECTIVES: Histologic diagnosis of malignant pleural mesothelioma (MPM) is not always straightforward. Loss of BRCA1-associated protein 1 (BAP1) expression as detected by immunohistochemistry (IHC) (BAP1 IHC) and […]

Comments Off on A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 cases.

Annals of Diagnostic Pathology 2018 October 28 [Link] Sun M, Zhao L, Weng Lao I, Yu L, Wang J Abstract We present our experience with 75 cases of well-differentiated papillary mesothelioma (WDPM) that were diagnosed at our institution between 2000 and 2017. The patients included 58 females and 17 males with age ranging from 18 […]

Comments Off on Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 cases.

Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

Medicine 2018 November [Link] Du Z, Yu Y, Wu D, Zhang G, Wang Y, He L, Meng R Abstract RATIONALE: Malignant Pleural Mesothelioma (MPM) is rare cancer and has a poor prognosis with resistance to chemotherapy or radiotherapy. Until now there is no standard third-line treatment for patients who have failed second-line therapy. PATIENT CONCERNS: […]

Comments Off on Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

Peripheral blood DNA methylation as potential biomarker of Malignant Pleural Mesothelioma in asbestos-exposed subjects.

Journal of Thoracic Oncology 2018 November 5 [Link] Guarrera S, Viberti C, Cugliari G, Allione A, Casalone E, Betti M, Ferrante D, Aspesi A, Casadio C, Grosso F, Libener R, Piccolini E, Mirabelli D, Dianzani I, Magnani C, Matullo G Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive tumour strongly associated with asbestos exposure. […]

Comments Off on Peripheral blood DNA methylation as potential biomarker of Malignant Pleural Mesothelioma in asbestos-exposed subjects.

Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Annals of Gastroenterology 2018 Nov-Dec [Link] Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, Katsanos KH, Christodoulou DK Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease with a wide clinical spectrum. It arises from the peritoneal lining and commonly presents with diffuse, extensive spread throughout the abdomen and, more rarely, […]

Comments Off on Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.

Journal of Cellular Biology 2018 October 26 [Link] Matboli M, Shafei AE, Ali MA, Gaber AI, Galal A, Tarek O, Marei M, Khairy E, El-Khazragy N, Anber N, Abdel Abstract -Rahman OAIM AND BACKGROUND: Malignant pleural mesothelioma (MPM) is a lethal cancer mainly caused by chronic exposure of asbestos. In this pilot study, we aimed […]

Comments Off on Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.

MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.

Histopathology 2018 October 17 [Link] Kai Y1,2, Amatya VJ1, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y Abstract AIMS: The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers to definitively diagnose epithelioid mesothelioma. The aim of this […]

Comments Off on MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.

Malignant pleural mesothelioma: The role of surgery

Revue de Pneumologie Clinique 2018 October 10 [Link] Fournel L1, Janet-Vendroux A2, Canny-Hamelin E2, Mansuet-Lupo A, Guinet C, Bobbio A, Damotte D, Alifano M Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare and highly aggressive disease, whose incidence is increasing. Asbestos is the primary causal agent. STATE OF KNOWLEDGE: Knowledge about MPM has evolved. […]

Comments Off on Malignant pleural mesothelioma: The role of surgery

Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.

Molecular Cancer 2018 October 11 [Link] Smeele P, d’Almeida SM, Meiller C, Chéné AL, Liddell C, Cellerin L, Montagne F, Deshayes S, Benziane S, Copin MC, Hofman P, Le Pimpec-Barthes F, Porte H, Scherpereel A, Grégoire M, Jean Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The discovery […]

Comments Off on Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.

[Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].

Revue de Pneumologie Clinique 2018 October 4 [Link] Mlika M, Lamzirbi O, Limam M, Mejri N, Ben Saad S, Chaouch N, Ben Miled K, Marghli A, Mezni F Abstract BACKGROUND: The malignant pleural mesothelioma (MPM) is a rare tumour usually associated to asbestos exposure. The delay between the exposure and the occurrence of the cancer […]

Comments Off on [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].